Grünenthal announced today that the first healthy volunteers have been enrolled in a Phase I trial of its voltage-gated sodium channel (NaV) 1.8 inhibitor. The orally administered investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results